MET · Q3 2025 Earnings

Q2 anchor → Q3 anchor: "Earnings power not fully evident" / VII forecasting difficulty → "Highest recent contribution" / ahead of New Frontier schedule.

On variable investment income, the spine of the Q2 cautious narrative. Last quarter management pre-announced VII in late September because it could not forecast its largest swing factor — McCallion's "once again" was the tell that this disclosure protocol was being repeated under pressure. This quarter VII delivered "its highest recent contribution to adjusted earnings," with private equity returning 3% in the quarter. The Q2 worry about a structurally lower forecasting confidence has, for now, been answered by the realized print. One quarter does not rebuild a forecasting reputation, but management is no longer framing VII as a headwind to be explained.

On the expense ratio, where management is pulling the New Frontier target forward. Last quarter the direct expense ratio was disclosed without forward conviction. This quarter the Q3 direct expense ratio printed at 11.6% and management is explicit: "We are well ahead of schedule with this ratio relative to our new frontier commitment with the force multiplier effect of AI and other emerging technologies." And on the call: "we will come in, you know, below the 12-1, I would say even well below the 12-1 at year end." The shift from aspirational target to "well below" with conviction is the most consequential forward signal in the print.

On PRT, which was Q2's "more to come" generality. Last quarter Chariot Re was framed as a vehicle launched July 1 with future tranches uncommitted. This quarter Chariot Re has executed its first $10B reinsurance transaction and MetLife has written $12B of direct PRT in Q4 alone, with management citing 94% of de-risking sponsors planning full divestment within five years — "the highest percentage we've recorded since we initiated the survey 10 years ago." Pipeline visibility is no longer a question; capacity to absorb it is.

On Mexico, the new known unknown. This is the only area where Q3 commentary introduces material downside. The VAT law change removes deductibility on the Mexico health product, producing a $20–25M after-tax Q4 charge and a $50–60M LATAM 2026 earnings reduction. Management says rate action will mitigate over time but is not putting a number on the recovery trajectory. This belongs on the watch list, not in the bull case.

On overall posture. Q2 introduced a defensive carve-out — "this quarter does not demonstrate the full earnings power." Q3 reverses it without a corresponding qualifier; the bullish themes (PRT, Asia, VII, expenses) are presented as durable rather than episodic. The vs-typical shift is toward confidence in execution rather than the cautious provisioning that characterized last quarter's framing.